Therapeutics

Senior Scientist of Computational Biologis Aarathi Sugathan uses genetic insights to identify and create actionable therapeutic targets for patients.

If you’re a recent Ph.D. graduate interested in opportunities to work with genetic data in the search for new insights into human disease and new treatments for those conditions, then...

Diseases are considered rare if they affect fewer than 200,000 in the United States, but collectively rare diseases — there are nearly 7,000 — are more common than we realize,...

23andMe's vice president for human genetics, Adam Auton, explains how our unique database shapes our approach to drug discovery. It begins with human genetics, but it doesn't end there. 

Both a physician and a scientist, John Mathews, a senior clinical development fellow on 23andMe’s Therapeutics team, said he is inspired by patients in the work he does, working where medicine and scientific discovery converge.

Kipper Fletez-Brant, a computational biologist with our Therapeutics division, thought he’d be a physicist one day.Growing up in Phoenix, Arizona, Kipper escaped the heat reading “hard-sci-fi novels” with mind-bending plots...

Xin Fang’s interest in science started at the dinner table, listening to her parents talking about what they did each day. Both her mom and dad are plant scientists. Her mom...

23andMe senior scientist in statistical genetics, Suyash Shringarpure, Ph.D. talks about 23andMe's research model and how it offers a surprising opportunity in the study of rare diseases.

A drug to fight cancer will be the first potential therapy to emerge from 23andMe and GlaxoSmithKline collaboration as the two companies announced that the new therapy will begin clinical trials.

23andMe's Head of Therapeutics Kenneth Hillan, M.B., Ch.B., discussed his career and the vision for 23andMe's work in therapeutics